CLARIUS-MOBILE-HEALTH
5.5.2022 09:17:13 CEST | Business Wire | Press release
Clarius Mobile Health is first to introduce a third-generation product line of high-performance wireless ultrasound scanners in the European Union and United Kingdom. Now 30% lighter and smaller, the new pocket-sized scanners that connect with Apple and Android devices are available today with revolutionary pricing and new features that will put premium handheld ultrasound into the hands of more doctors. Clarius has replaced the complex knobs and buttons found on traditional ultrasound systems with an app that uses artificial intelligence and intuitive touch-based controls. Thousands of first and second generation Clarius scanners are already in use across the continent to improve diagnostic speed and accuracy and improve procedural safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005072/en/
“Clinicians in Europe and the UK have been early adopters of Clarius wireless ultrasound, and we know excitement has been building for our new miniaturized Clarius HD3 because we’ve had a long list of customers eagerly waiting for CE certification,” says Clarius Founder Laurent Pelissier. “Our mission has always been to improve patient care by enabling more clinicians to use ultrasound. Now that Clarius is reduced to the size of an iPhone, easier to use, and costs less, we’re expecting more clinicians will use ultrasound to deliver the best patient care.”
In emergency environments, the Clarius C3 HD3 multipurpose scanner saves lives. Dr. Wolfgang Fleischmann, an anesthesiologist and emergency medicine physician, describes why the Red Cross chose Clarius when it sought to equip its emergency services vehicles with hospital-grade portable ultrasound.
“We had the opportunity to extensively test the Clarius scanner in our prehospital emergency environment. The product impressed us with its image quality, its reliability, its short start-up time, and good price-to-performance ratio. It prompted us to equip all our emergency doctors’ cars and ambulances with the Clarius ultrasound device.”
Clarius sets itself apart from other handheld ultrasound systems with exceptional imaging quality that rivals expensive cart-based systems, wireless connectivity, and specialty scanners with Software-as-a-Service (SaaS) designed to optimize clarity and workflows for different anatomy and applications. Clinicians can choose from seven ultrasound scanners, each designed to meet the specific requirements of a broad range of medical specialties.
With best-in-class MSK imaging, the Clarius L15 HD3 high-frequency linear scanner is a top choice amongst orthopaedic surgeons. Dr. Rudolf Berlakovits, MD, PhD, an orthopaedic surgeon in Vienna, Austria, describes the advantages of the new Clarius HD3 for safe, procedural guidance.
"To me as an orthopedic surgeon, the Clarius HD3 is a highly recommended device for interventional orthopedics and ultrasound guided orthopedic surgery. There is no cable, making it easy to keep aseptic, and the probe provides perfect handling. Another really great benefit is the possibility to share the findings with colleagues all over the world in real-time with Clarius Cloud exam management."
Clarius offers software packages designed for many specialty applications including Advanced Breast , Musculoskeletal , Obstetrics , Primary/Critical Care , Vascular , Veterinary Packages , and Aesthetics . They deliver dedicated presets, advanced workflows, comprehensive measurements, and fined tuned imaging, leveraging artificial intelligence and SaaS to deliver a complete handheld ultrasound solution that’s connected to the cloud.
Dr. Ines Verner, an Aesthetic Dermatologist based in Tel-Aviv, uses the Clarius L20 wireless ultrasound scanner to prevent complications such as vascular occlusions during aesthetic procedures like cosmetic fillers. She was among the first to try the Clarius L20 HD3 for facial aesthetics.
“It’s a breakthrough in the field. Clarius is a good fit for aesthetics because it lets me clearly see fine facial anatomy, it’s easy to use, the image quality is good, it’s wireless, and it’s small so I can take it with me from room to room,” Dr. Verner says. “Ultrasound is a gamechanger for the aesthetics industry because we can really see what we need to see instead of injecting blindly, which is what most of us used to do. Now, we can inject knowing where we’re going and not to inject where we don’t want to inject.”
New Membership Enables Ultrasound Mastery at a Lower Price
Clarius has introduced a new Clarius Membership bundle that makes the entry price lower and enables new users to fast-track ultrasound proficiency. Clarius HD3 wireless scanners now start at 2875 EUR with a 575 annual membership in Europe or 2440 GBP with 490 membership annual membership in the United Kingdom. Members gain access to all advanced SaaS, enhanced education options, and unlimited exam management in the Clarius Cloud. A three-year standard warranty is included with enhanced warranty options available through Clarius Care.
About Clarius Mobile Health
Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost. More than two million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005072/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
